Overview
ACIU market data
Price History
ACIU price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.70 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.56 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.03 – $4.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $226.4 · P/B 5.64 · P/S 49.86.
Company news
AC Immune Announces Three Presentations At The Alzheimer's Association International Conference, July 12-15Benzinga · Jul 7, 2026, 11:15 AM
AC Immune Announces Interim 12-Month Data From Its Phase 1b/2 ABATE Trial Of ACI-24 In Prodromal Alzheimer’s Disease; ACI-24 Generally Safe And Well Tolerated in First Three CohortsBenzinga · Jun 30, 2026, 11:20 AM
AC Immune Gets $4M Grant for Parkinson's Trial ExtensionBenzinga · Jun 11, 2026, 11:05 AM
AC Immune Presents New Preliminary Data From Phase 1 Trial Of TDP-43 Positron Emission Tomography Tracer ACI-19626 Showing Increased Uptake In Brains Of Patients With Amyotrophic Lateral SclerosisBenzinga · May 22, 2026, 11:15 AM
AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patients with ALSGlobenewswire Inc · May 22, 2026, 11:15 AM